KBC Securities - Biotalys NV (BTLS) BIOTALYS: Putting puzzle pieces together BTLS BB

Report

KBC Securities

Guy Sips

BIOTALYS: Putting puzzle pieces together BTLS BB

Biotalys is a green AgTech, Agricultural Technology, company that develops biological crop and food protection products based on a proprietary antibody-based technology shaping the future of sustainable and safe food supply.
Over recent months, Biotalys signed -as part of its flexible, capital light business model- important long-term strategic partnerships with Biobest and Olon, putting puzzle pieces together.

12/01/2022 1 EN

Underlying

Biotalys NV

See profile

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Other Reports on these Companies

KBC Securities

Morning Note: AZE BB, BTLS BB, MITRA BB, Telecom BE

Azelis: Expansion into South America Biotalys: Partnership with Novozymes for Evoca Mithra: Additional details on private placement Telecom: Results mobile spectrum auction

June 21, 2022 June 21, 2022 1 EN

KBC Securities

KBCS New Horizon Conference Book AGFB BB, ARCAD NA, ASML NA, BAR BB, BTLS BB, DIE BB, EKOP BB, HYL BB, IBAB BB, MITRA BB, TWEKA NA

On Thursday 9 June, we organise our first New Horizon Conference in London. Following listed companies will be presented: • ASML • Agfa • Arcadis • Barco • Biotalys • D'Ieteren • Ebusco • Ekopak • Hyloris • IBA • Mithra • TKH We give a summary of our view on the companies we welcome, with key investment metrics that can serve as a guide during your meeting(s).

June 7, 2022 June 7, 2022 1 EN

KBC Securities

Morning Note: ASC BB, AZE BB, BTLS BB, COFB BB, EKOP BB

Ascencio: 1H21/22 Slightly ahead of expectations Azelis: Initiation - Formula for success, at a price Biotalys: BioProtection Award 2022 for Best Biofungicide Cofinimmo: Clearing out the old Offices Ekopak: Update on roll-out in France Various: Coverage update

May 25, 2022 May 25, 2022 1 EN

Galapagos GLPG3667 phase 2 hits topline in DM, but misses in SLE

Galapagos announced the topline results from 2 phase 2 studies evaluating the efficacy and safety of GLPG3667 (TYK2 inhibitor) in dermatomyositis (DM, GALARISSO study) and active systemic lupus erythematosus (SLE, GALACELA study). The GALARISSO study in DM met its primary endpoint showing a 14.26 delta on the TIS measure at 24 weeks, which compares favourably to brepocitinib (TYK2/JAK1 inhibitor) in our view. In the GALACELA study in SLE patients, primary endpoint at 32 weeks was not met, but final data at 48 weeks in 2Q26 will inform next steps. Galapagos will evaluate all strategic alternati...

December 19, 2025 December 19, 2025 1 EN

Guy Sips ... (+8)

Guy Sips
Hilde Van Boxstael
Jacob Mekhael
Kristof Samoy
Livio Luyten
Michiel Declercq
Thibault Leneeuw
Wim Lewi

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

December 19, 2025 December 19, 2025 1 EN

Kristof Samoy

Kristof Samoy

NX Filtration Trouble comes in fours, yet another profit warning eroding investor trust

NX Filtration just sent out another profit warning. For the fourth time in a row the company confessed it will not be able to realise its issued revenue guidance. At the 1H25 release the company reiterated its FY25 revenue guidance calling for y/y growth in the 50-70% range with KBC est. at the 60% midpoint. Today management warns FY25 revs are expected to be ca. €14m, representing a y/y growth just topping 25%. No quantified insights in profitability and cash position were given but surprisingly average yearly growth targets of 50% were reiterated. With no credible pathway to delivery on thes...

December 19, 2025 December 19, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BIOTALYS: Putting puzzle pieces together BTLS BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Note: AZE BB, BTLS BB, MITRA BB, Telecom BE

KBCS New Horizon Conference Book AGFB BB, ARCAD NA, ASML NA, BAR BB, BTLS BB, DIE BB, EKOP BB, HYL BB, IBAB BB, MITRA BB, TWEKA NA

Morning Note: ASC BB, AZE BB, BTLS BB, COFB BB, EKOP BB

Galapagos GLPG3667 phase 2 hits topline in DM, but misses in SLE

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

NX Filtration Trouble comes in fours, yet another profit warning eroding investor trust

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe